Aerovate Therapeutics, Inc. – NASDAQ:AVTE

Add to watchlist

$2.68

+0.01

+0.37%

Market open

Closed in about 5 hours

+47.51%

month

+47.51%

quarter

-88.99%

year

Market Cap	73.19M
Enterprise value	437.54M

P/E	-9.06
EV/Sales	N/A
EV/EBITDA	-5.86
Price/Sales	N/A
Price/Book	3.62
PEG ratio	-0.11
EPS	-3.04

Revenue	N/A
EBITDA	-88.31M
Income	-82.18M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Aerovate Therapeutics, Inc. (NASDAQ:AVTE): Profit margin
Jun 2023	0	-19.02M
Sep 2023	0	-19.56M
Dec 2023	136K	-20.41M	-15009.56%
Mar 2024	0	-23.18M

Aerovate Therapeutics Financials Estimate

Q Y

Aerovate Therapeutics, Inc. (NASDAQ:AVTE): Analyst Estimates
Sep 2025	0	-19.50M
Oct 2025	0	-7.08M
Dec 2025	0	-3.19M
Mar 2026	0	-20.22M

Analysts Price target
Financials & Ratios estimates

Aerovate Therapeutics, Inc. (NASDAQ:AVTE): Earnings per share (EPS)
2024-03-25	-0.68	-0.74
2024-05-13	-0.74	-0.83

Aerovate Therapeutics, Inc. (NASDAQ:AVTE): Debt to assets
Jun 2023	155755000	13.82M	8.88%
Sep 2023	140876000	15.15M	10.76%
Dec 2023	127418000	17.96M	14.1%
Mar 2024	106821000	15.91M	14.9%

Aerovate Therapeutics, Inc. (NASDAQ:AVTE): Cash Flow
Jun 2023	-14.94M	3.98M	45.29M
Sep 2023	-15.61M	-13.13M	20K
Dec 2023	-14.8M	5.64M	463K
Mar 2024	-23.67M	8.83M	471K

Aerovate Therapeutics alternative data

Aerovate Therapeutics
Employees

Aerovate Therapeutics, Inc. (NASDAQ:AVTE): Employee count
Aug 2023	43
Sep 2023	43
Oct 2023	43
Nov 2023	43
Dec 2023	43
Jan 2024	43
Feb 2024	43
Mar 2024	51
Apr 2024	51
May 2024	51
Jun 2024	51
Jul 2024	51

Aerovate Therapeutics
Hedge Funds Holdings Q1 2023

23.77% -76.23%

of AVTE is owned by hedge funds

28 -41

hedge funds hold AVTE stock

5.81M -21.58M

shares is hold by hedge funds

AVTE hedge funds holdings changes

Aerovate Therapeutics
Insider Trading

Aerovate Therapeutics, Inc. (NASDAQ:AVTE): Insider trades (number of shares)
Period	Buy	Sel
Jun 2023	0	12533
Jul 2023	0	32533
Aug 2023	0	10283
Sep 2023	0	3961
Nov 2023	0	2062
Feb 2024	0	511
Mar 2024	0	109832
Apr 2024	0	71355
May 2024	0	27338

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Sale	17 May 2024	GILLIES HUNTER officer: CHIEF ME..	Common Stock	86	$21.86	$1,880
Option	17 May 2024	GILLIES HUNTER officer: CHIEF ME..	Stock Option (Right to Buy)	4,000	$2.14	$8,560
Option	17 May 2024	GILLIES HUNTER officer: CHIEF ME..	Common Stock	4,000	$2.14	$8,560
Sale	17 May 2024	GILLIES HUNTER officer: CHIEF ME..	Common Stock	3,914	$21.07	$82,452
Option	16 May 2024	NOYES TIMOTHY P director, officer: CHIEF EXECUTIVE OFFICER director, officer: CHIEF EXECUT..	Stock Option (Right to Buy)	10,000	$2.14	$21,400
Option	16 May 2024	NOYES TIMOTHY P director, officer: CHIEF EXECUTIVE OFFICER director, officer: CHIEF EXECUT..	Common Stock	10,000	$2.14	$21,400
Sale	16 May 2024	NOYES TIMOTHY P director, officer: CHIEF EXECUTIVE OFFICER director, officer: CHIEF EXECUT..	Common Stock	8,707	$21.52	$187,409
Sale	16 May 2024	NOYES TIMOTHY P director, officer: CHIEF EXECUTIVE OFFICER director, officer: CHIEF EXECUT..	Common Stock	1,293	$21.92	$28,345
Sale	2 May 2024	VERWIJS MARINUS officer: CHIEF TECHNICAL OFFICER officer: CHIEF TECHNICAL OFFICER	Common Stock	1,981	$21.02	$41,631
Option	1 May 2024	NOYES TIMOTHY P director, officer: CHIEF EXECUTIVE OFFICER director, officer: CHIEF EXECUT..	Stock Option (Right to Buy)	10,000	$2.14	$21,400

AVTE insider trading transactions

Status	Patent	Filling date	Issue date
Application	Application INHALABLE IMATINIB FORMULATIONS, MANUFACTURE, AND USES THEREOF Filling date: 24 Jan 2022 Issue date: 14 Jul 2022	24 Jan 2022	14 Jul 2022
Application	Application NEBULIZED IMATINIB FORMULATIONS, MANUFACTURE, AND USES THEREOF Filling date: 3 Mar 2022 Issue date: 16 Jun 2022	3 Mar 2022	16 Jun 2022
Grant	Grant Utility: Inhalable imatinib formulations, manufacture, and uses thereof Filling date: 14 May 2020 Issue date: 12 Apr 2022	14 May 2020	12 Apr 2022
Grant	Grant Utility: Inhalable imatinib formulations, manufacture, and uses thereof Filling date: 14 May 2020 Issue date: 25 Jan 2022	14 May 2020	25 Jan 2022
Application	Application INHALABLE IMATINIB FORMULATIONS, MANUFACTURE, AND USES THEREOF Filling date: 14 May 2020 Issue date: 3 Dec 2020	14 May 2020	3 Dec 2020
Application	Application INHALABLE FORMULATIONS FOR KINASE INHIBITION Filling date: 14 May 2020 Issue date: 19 Nov 2020	14 May 2020	19 Nov 2020
Application	Application INHALABLE IMATINIB FORMULATIONS, MANUFACTURE, AND USES THEREOF Filling date: 14 May 2020 Issue date: 19 Nov 2020	14 May 2020	19 Nov 2020
Application	Application INHALABLE IMATINIB FORMULATIONS, MANUFACTURE, AND USES THEREOF Filling date: 14 May 2020 Issue date: 19 Nov 2020	14 May 2020	19 Nov 2020
Application	Application NEBULIZED IMATINIB FORMULATIONS, MANUFACTURE, AND USES THEREOF Filling date: 14 May 2020 Issue date: 19 Nov 2020	14 May 2020	19 Nov 2020
Application	Application INHALABLE FORMULATIONS OF IMATINIB, IMATINIB METABOLITES, IMATINIB SALTS, THEIR MANUFACTURE, AND USES THEREOF Filling date: 14 May 2020 Issue date: 19 Nov 2020	14 May 2020	19 Nov 2020

Aerovate Therapeutics
Executives

Insider	Age	Compensation
Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.S (1960) Chief Devel. Officer	65	$372,330
Mr. Hunter Gillies M.D. (1966) Chief Medical Officer	59	$362,350
Dr. Benjamin T. Dake Ph.D. (1976) Founder, Pres, Chief Operating Officer & Sec.	49	$327,210

Aerovate Therapeutics
Latest News

Saturday, 28 December 2024
13:32	AVTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc. Is Fair to Shareholders	businesswire.com
Tuesday, 5 November 2024
18:53	INVESTOR ALERT: The M&A Class Action Firm Investigates the Merger of Aerovate Therapeutics, Inc. – AVTE	globenewswire.com
Sunday, 3 November 2024
15:47	INVESTOR ALERT: The M&A Class Action Firm Investigates the Merger of Aerovate Therapeutics, Inc. - AVTE	prnewswire.com
Friday, 1 November 2024
12:02	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders	prnewswire.com
Thursday, 31 October 2024
09:43	AVTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc. Is Fair to Shareholders	businesswire.com
09:31	Shareholder Alert: Ademi LLP Investigates Whether Aerovate Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders	businesswire.com
Monday, 8 July 2024
08:00	Aerovate Therapeutics to Explore Strategic Alternatives	globenewswire.com
Thursday, 27 June 2024
07:00	The 3 Hottest Stock Downgrades From Last Week	investorplace.com
Friday, 21 June 2024
14:00	Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC	globenewswire.com
Thursday, 20 June 2024
13:22	Aerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law Firm	globenewswire.com
Tuesday, 18 June 2024
10:25	Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals	zacks.com
Monday, 17 June 2024
12:07	SHAREHOLDER ALERT: Aerovate Therapeutics Investigated for Securities Fraud Violations by Block & Leviton	globenewswire.com
08:32	Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension	globenewswire.com
Tuesday, 11 June 2024
13:19	Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market	seekingalpha.com
Tuesday, 21 May 2024
16:15	Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference	globenewswire.com
Monday, 13 May 2024
16:30	Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights	globenewswire.com
Wednesday, 27 March 2024
09:20	Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference	GlobeNewsWire
Thursday, 1 June 2023
08:00	Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference	GlobeNewsWire
Wednesday, 12 April 2023
08:45	Aerovate: Small Mid-Stage Biotech Targeting Multibillion-Dollar PAH Market	Seeking Alpha
Thursday, 2 March 2023
08:00	Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference	GlobeNewsWire
Sunday, 29 January 2023
07:12	Aerovate: Developing An Exciting PAH Drug, Initiating With A Buy	Seeking Alpha
Monday, 18 October 2021
17:27	AVTE Stock Increases On High Volume	Pulse2
Friday, 17 September 2021
08:00	Aerovate Therapeutics Announces Its Addition to the Russell 2000® Index	GlobeNewsWire

Ideas & Opinions

Seeking Alpha 11 Jun 2024

Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market
Seeking Alpha 28 Jun 2023

Aerovate: Smart Investment Opportunity With This Developer Of Inhaled Imatinib For PAH
Seeking Alpha 12 Apr 2023

Aerovate: Small Mid-Stage Biotech Targeting Multibillion-Dollar PAH Market
Seeking Alpha 30 Jan 2023

Gossamer: Disappointing Phase 2 Results But Too Cheap To Ignore
Seeking Alpha 29 Jan 2023

Aerovate: Developing An Exciting PAH Drug, Initiating With A Buy
Seeking Alpha 8 Dec 2022

Gossamer Bio: Buying The Savage Dip After A Trial 'Win' May Be Unwise

Frequently Asked Questions (FAQ)

What's the price of Aerovate Therapeutics stock today?

One share of Aerovate Therapeutics stock can currently be purchased for approximately $2.68.
When is Aerovate Therapeutics's next earnings date?

Unfortunately, Aerovate Therapeutics's (AVTE) next earnings date is currently unknown.
Does Aerovate Therapeutics pay dividends?

No, Aerovate Therapeutics does not pay dividends.
How much money does Aerovate Therapeutics make?

Aerovate Therapeutics has a market capitalization of 73.19M. Aerovate Therapeutics made a loss 75.52M US dollars in net income (profit) last year or -$0.83 on an earnings per share basis.
What is Aerovate Therapeutics's stock symbol?

Aerovate Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "AVTE".
What is Aerovate Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Aerovate Therapeutics?

Shares of Aerovate Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Aerovate Therapeutics's key executives?
Aerovate Therapeutics's management team includes the following people:
- Dr. Ralph W. Niven M.B.A., M.R, Ph.D., Pharm.S Chief Devel. Officer(age: 65, pay: $372,330)
- Mr. Hunter Gillies M.D. Chief Medical Officer(age: 59, pay: $362,350)
- Dr. Benjamin T. Dake Ph.D. Founder, Pres, Chief Operating Officer & Sec.(age: 49, pay: $327,210)
Is Aerovate Therapeutics founder-led company?

Yes, Aerovate Therapeutics is a company led by its founder Dr. Benjamin T. Dake Ph.D..
How many employees does Aerovate Therapeutics have?

As Jul 2024, Aerovate Therapeutics employs 51 workers.
When Aerovate Therapeutics went public?

Aerovate Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 30 Jun 2021.
What is Aerovate Therapeutics's official website?

The official website for Aerovate Therapeutics is aerovatetx.com.
Where are Aerovate Therapeutics's headquarters?

Aerovate Therapeutics is headquartered at 930 Winter Street, Waltham, MA.
How can i contact Aerovate Therapeutics?

Aerovate Therapeutics's mailing address is 930 Winter Street, Waltham, MA and company can be reached via phone at +61 74432400.

Aerovate Therapeutics, Inc.

aerovatetx.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

+61 74432400

930 Winter Street
Waltham, MA 02116

CIK: 0001798749
ISIN: US0080641071
CUSIP: 008064107